Patents by Inventor Paula M. Cannon

Paula M. Cannon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Delivery methods and compositions for nuclease-mediated genome engineering
    Patent number: 10604771
    Abstract: Disclosed herein are methods and compositions for delivery of engineered nucleases and donor molecules into the genome of a cell.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: March 31, 2020
    Assignees: Sangamo Therapeutics, Inc., University of Southern California
    Inventors: Paula M. Cannon, Colin Michael Exline, Michael C. Holmes
  • Gene editing for HIV gene therapy
    Patent number: 9757420
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted integration of anti-HIV transgenes into the genome of a cell for the treatment and/or prevention of HIV.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: September 12, 2017
    Assignees: Sangamo Therapeutics, Inc., University of Southern California
    Inventors: Philip D. Gregory, Jianbin Wang, Paula M. Cannon
  • GENE EDITING FOR HIV GENE THERAPY
    Publication number: 20160022737
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted integration of anti-HIV transgenes into the genome of a cell for the treatment and/or prevention of HIV.
    Type: Application
    Filed: July 23, 2015
    Publication date: January 28, 2016
    Inventors: Philip D. Gregory, Jianbin Wang, Paula M. Cannon
  • DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING
    Publication number: 20140335063
    Abstract: Disclosed herein are methods and compositions for delivery of engineered nucleases and donor molecules into the genome of a cell.
    Type: Application
    Filed: May 6, 2014
    Publication date: November 13, 2014
    Inventors: Paula M. Cannon, Colin Michael Exline, Michael C. Holmes
  • Anti-HIV peptides and proteins
    Patent number: 6287572
    Abstract: This invention relates to novel peptides and proteins and nucleic acids encoding them, which are useful against HIV infection. The peptides comprise an amino acid sequence of a part of the HIV-1 p17 protein or of the HIV-2 p16 protein, from amino acid residues 31 to 45 or from amino acid residues 41 to 55. The proteins are recombinant p16 and p17 proteins having an alteration in helix A which is defined by amino acid residues 31 to 46, or the A-B loop which is defined by amino acid residues 47 to 52.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: September 11, 2001
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Alan J. Kingsman, Susan M. Kingsman, Paula M. Cannon